Position in EXEL
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$6,839,445
+$1,251,222 QoQ
Shares Held
125,702
-3.5% QoQ
Ownership
0.051%
of shares outstanding
% of Portfolio
0.98%
of 13F equity value
Holder Rank
#148
of 751 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026L2 Asset Management, LLC holds $28,710,157 across 7 Biotechnology names. EXEL ranks #3 (23.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RPRX |
Royalty Pharma plc
|
129,324 | $7,251,196 | |
| 2 | INCY |
Incyte Corp
|
61,784 | $7,003,834 | |
| 3 | EXEL |
Exelixis, Inc.
This page
|
125,702 | $6,839,445 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
27,290 | $6,576,071 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
952 | $593,610 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
768 | $231,191 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
1,147 | $214,810 |
All Filings in EXEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,839,445 | 125,702 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $5,588,223 | 130,292 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,798,570 | 86,666 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $3,364,215 | 81,458 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||